RxDoctor Payments Data

Manish Viradia, MD

Neurology · Annandale, NJNPI 1457345324

Payments from drug & device makers

$30,209in general payments, 2019–2025

Across 1,345 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$7K
  • Genentech USA, Inc.$7K
  • AbbVie$3K
  • Biogen$2K
  • Novartis$1K
  • Lilly USA, LLC$935
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$4,50015%
  • Speaking & faculty fees$5,20417%
  • Travel & lodging$2,3998%
  • Food & beverage$17,95659%
  • Education$1500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.41$6,697
Genentech USA, Inc.47$6,626
AbbVie(2 entities)247$2,814
Biogen98$1,503
Novartis86$1,050
Lilly USA, LLC58$935
Teva Pharmaceuticals USA, Inc.90$899
Eisai Inc.42$755
Amneal Pharmaceuticals LLC58$722
UCB, Inc.51$692
Pfizer51$616
EMD Serono, Inc.41$491
Lundbeck LLC35$457
Supernus Pharmaceuticals, Inc.37$438
AstraZeneca(2 entities)25$399
Amgen(2 entities)28$373
Bristol Myers Squibb19$280
CSL Behring17$271
Kyowa Kirin, Inc.18$256
Johnson & Johnson(2 entities)19$237
SK Life Science, Inc.12$185
Acorda Therapeutics, Inc13$182
Jazz Pharmaceuticals Inc.12$180
Sunovion Pharmaceuticals Inc.10$175
Axsome Therapeutics, Inc.11$169
Otsuka America Pharmaceutical, Inc.9$138
Adamas Pharmaceuticals, Inc.9$130
Boston Scientific4$129
Sanofi10$125
Scilex Pharmaceuticals Inc.8$119
TG Therapeutics, Inc.6$117
Acadia Pharmaceuticals Inc8$116
Grifols USA, LLC7$114
Amylyx Pharmaceuticals, Inc.6$101
Mallinckrodt Hospital Products Inc.6$88
Biohaven Pharmaceutical Holding Company Ltd.6$85
Alnylam Pharmaceuticals Inc.5$84
ANI Pharmaceuticals, Inc.5$79
Mallinckrodt Enterprises LLC5$73
Neurelis, Inc.5$72
Revance Therapeutics, Inc.3$71
GE HealthCare5$71
Neurocrine Biosciences, Inc.4$70
MDD US Operations, LLC5$68
Takeda Pharmaceuticals U.S.A., Inc.4$66
Harmony Biosciences LLC3$56
Impel Pharmaceuticals Inc.3$52
Akcea Therapeutics, Inc.3$46
Aquestive Therapeutics, Inc.3$42
Abbott1$38
Arbor Pharmaceuticals, Inc.3$38
Azurity Pharmaceuticals, Inc.2$34
Insightec,inc2$34
Inspire Medical Systems, Inc.2$33
Vanda Pharmaceuticals Inc.2$32
Octapharma USA, Inc.2$30
Merz Pharmaceuticals, LLC2$29
Promius Pharma LLC2$29
Avanir Pharmaceuticals, Inc.2$28
Avion Pharmaceuticals2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,209 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$8,554,958
Medicare patients
756
Services billed
411,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5096$1,312,394
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5041$722,143
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5016$464,340
AustedoDeutetrabenazine34$294,616
Austedo XrDeutetrabenazine37$281,502
NuplazidPimavanserin Tartrate22$168,530
Lamictal XrLamotrigine23$123,327
Kesimpta PenOfatumumab11$92,363
IngrezzaValbenazine Tosylate12$92,078
UbrelvyUbrogepant64$83,564
RytaryCarbidopa/Levodopa107$81,271
Nurtec OdtRimegepant Sulfate46$71,512
QuliptaAtogepant54$56,800
TopamaxTopiramate39$56,045
NourianzIstradefylline19$44,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Eliquis$616$1,402,465156 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Vyvanse$66$728,04157 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$899$576,11871 claims
AbbVieUbrelvy, Qulipta, Botox, Namzaric$2,814$199,963156 claims
Acadia Pharmaceuticals IncNuplazid$116$168,53022 claims
Neurocrine Biosciences, Inc.Ingrezza$70$92,07812 claims
Amneal Pharmaceuticals LLCRytary$722$81,271107 claims
Kyowa Kirin, Inc.Nourianz$256$44,85619 claims
UCB, Inc.Nayzilam$692$29,37127 claims
Eisai Inc.Fycompa$755$8,32813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Annandale

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →